This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 Apr 16;100(8):521-3.

doi: 10.1093/jnci/djn098. Epub 2008 Apr 8.

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

Francisco J Esteva, Gabriel N Hortobagyi

PMID: 18398093
DOI: 10.1093/jnci/djn098

Editorial

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

Francisco J Esteva et al. J Natl Cancer Inst. 2008.

. 2008 Apr 16;100(8):521-3.

doi: 10.1093/jnci/djn098. Epub 2008 Apr 8.

Authors

Francisco J Esteva, Gabriel N Hortobagyi

PMID: 18398093
DOI: 10.1093/jnci/djn098

No abstract available

PubMed Disclaimer

Comment on

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group. von Minckwitz G, et al. J Natl Cancer Inst. 2008 Apr 16;100(8):552-62. doi: 10.1093/jnci/djn089. Epub 2008 Apr 8. J Natl Cancer Inst. 2008. PMID: 18398094 Clinical Trial.
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group. von Minckwitz G, et al. J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. doi: 10.1093/jnci/djn085. Epub 2008 Apr 8. J Natl Cancer Inst. 2008. PMID: 18398097 Clinical Trial.

Similar articles

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group. von Minckwitz G, et al. J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. doi: 10.1093/jnci/djn085. Epub 2008 Apr 8. J Natl Cancer Inst. 2008. PMID: 18398097 Clinical Trial.
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J. Jeong JH, et al. Invest New Drugs. 2012 Feb;30(1):408-16. doi: 10.1007/s10637-010-9555-7. Epub 2010 Oct 5. Invest New Drugs. 2012. PMID: 20922557
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S. Huober J, et al. Breast Cancer Res Treat. 2010 Nov;124(1):133-40. doi: 10.1007/s10549-010-1103-9. Epub 2010 Aug 10. Breast Cancer Res Treat. 2010. PMID: 20697801 Clinical Trial.
Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N, Safra T. Yaal-Hahoshen N, et al. Isr Med Assoc J. 2006 Jun;8(6):416-21. Isr Med Assoc J. 2006. PMID: 16833172 Review. No abstract available.
Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
von Minckwitz G, Fontanella C. von Minckwitz G, et al. Breast. 2013 Aug;22 Suppl 2:S149-51. doi: 10.1016/j.breast.2013.07.028. Breast. 2013. PMID: 24074777 Review.

See all similar articles

Cited by

To measure the unmeasurable.
Gnant M. Gnant M. World J Surg. 2009 Jan;33(1):52-3. doi: 10.1007/s00268-008-9801-8. World J Surg. 2009. PMID: 19015915 No abstract available.
Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer.
Moon HG, Yi JK, Kim HS, Lee HY, Lee KM, Yi M, Ahn S, Shin HC, Ju JH, Shin I, Han W, Noh DY. Moon HG, et al. BMC Cancer. 2012 Dec 10;12:585. doi: 10.1186/1471-2407-12-585. BMC Cancer. 2012. PMID: 23216670 Free PMC article.
Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review.
Prevos R, Smidt ML, Tjan-Heijnen VC, van Goethem M, Beets-Tan RG, Wildberger JE, Lobbes MB. Prevos R, et al. Eur Radiol. 2012 Dec;22(12):2607-16. doi: 10.1007/s00330-012-2653-5. Epub 2012 Sep 16. Eur Radiol. 2012. PMID: 22983282
Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes.
Jiang S, Pogue BW, Carpenter CM, Poplack SP, Wells WA, Kogel CA, Forero JA, Muffly LS, Schwartz GN, Paulsen KD, Kaufman PA. Jiang S, et al. Radiology. 2009 Aug;252(2):551-60. doi: 10.1148/radiol.2522081202. Epub 2009 Jun 9. Radiology. 2009. PMID: 19508985 Free PMC article. Clinical Trial.
Preoperative systemic chemotherapy and pathologic assessment of response.
Pusztai L. Pusztai L. Pathol Oncol Res. 2008 Jun;14(2):169-71. doi: 10.1007/s12253-008-9070-8. Epub 2008 Jun 13. Pathol Oncol Res. 2008. PMID: 18553157

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information